← Browse by Condition

Medical Condition

nsclc

Total Trials

20

Recruiting Now

20

Trial Phases

Phase 1, Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for nsclc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — nsclc Clinical Trials

How many clinical trials are currently recruiting for nsclc?

ClinicalMetric currently tracks 20 actively recruiting clinical trials for nsclc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 20. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for nsclc?

nsclc research spans Phase 1 (4 trials), Phase 2 (6 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a nsclc clinical trial?

Eligibility criteria for nsclc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

4

Phase 2

6

Phase 3

1

Top Sponsors

Second Hospital of Shanxi Medical University 1 trial

Karsten Gavenis 1 trial

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 1 trial

Merck Sharp & Dohme LLC 1 trial

HC Biopharma Inc. 1 trial

Recruiting Clinical Trials

Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC

Second Hospital of Shanxi Medi...

Validation of the TheraSure CNI-Monitor Under Immuno-checkpoint-therapy (Hereinafter: "Immunotherapy") in NSCLC in Palliative Therapy

Karsten Gavenis

NCT06917079 Phase 1

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

United States, Austr...

TheRas, Inc., d/b/a BBOT (Brid...

NCT06422143 Phase 3

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

United States, Argen...

Merck Sharp & Dohme LLC

NCT07169552 Phase 2

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients

HC Biopharma Inc.

NCT06789172 Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

United States, Austr...

NCT07264673 Phase 2

A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.

Fondazione Ricerca Traslaziona...

NCT06221670 Phase 2

Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)

Tianjin Medical University Can...

Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC

Fondazione del Piemonte per l'...

Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer

Shanghai Cancer Hospital, Chin...

NCT06532591 Phase 2

Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC

Sichuan Cancer Hospital and Re...

NCT05798845 Phase 2

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

Shanghai Chest Hospital

Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo

NCT07397338 Phase 1, Phase 2

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Revolution Medicines, Inc.

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Fondazione IRCCS Istituto Nazi...

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer

Energenx Medical LTD.

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

Belgium, Italy, Neth...

European Organisation for Rese...

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）

Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

University of Erlangen-Nürnber...

NCT06816108 Phase 1

A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

Ono Pharmaceutical Co., Ltd.

Related Conditions

non small cell lung cancer (4) hnscc (2) colorectal cancer crc (2) breast cancer (2) renal cell carcinoma (2) nintedanib (1) radiation pneumonitis (1) pdac pancreatic ductal adenocarcinoma (1) crc colorectal cancer (1) metastatic non small lung cell cancer (1) metastatic colorectal cancer crc (1) kras g12a (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology